查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球藥物發現市場評估：依藥物類型、原產地、技術、最終使用者、地區、機會、預測（2017-2031）
市場調查報告書
商品編碼
1408033

全球藥物發現市場評估：依藥物類型、原產地、技術、最終使用者、地區、機會、預測（2017-2031）

Global Drug Discovery Market Assessment, By Drug Type, By Source, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 218 Pages | 商品交期: 3-5個工作天內

價格

全球藥物發現市場規模預計到 2023 年將達到 682.4 億美元，到 2031 年將達到 1541.2 億美元，2024-2031 年預測期間複合年增長率為 10.72%。我是。 市場成長受到多種因素的推動，例如各種慢性病的流行、醫療保健支出的增加、某些常見藥物的專利到期、人工智慧解決方案的採用以及公共和私營部門對生物醫學研究的投資增加。

由於人口老化的增加，市場顯示出更強勁的成長。 出生率下降、醫療設施增加導致預期壽命延長，以及世界各地針對老齡化人口的大量治療選擇，這些都是幫助人們延長壽命的因素。 然而，這進一步加速了老年人與年齡相關的疾病和慢性疾病的發生。 與此類模式競爭需要藥物發現的創新和研發。 此外，每個國家都有法規負責確保和維持各個階段藥品的品質和標準，以檢查批准藥品的安全性和有效性，並改善人民的健康。

COVID-19 大流行加速了護理流動，導致各國醫療保健支出增加。 由於研究、藥物開發和製造流程支出的增加，全球藥物發現市場的醫療保健成本不斷上升。 藥物發現是一個昂貴、複雜且微妙的過程，由於藥物研發的成本和風險，需要政府和製藥公司的資助。 醫療保健支出可以帶來更好的健康機會，進一步加強一個國家的醫療保健系統，並擴大全球藥物發現市場。

慢性病流行

慢性病的流行是市場的主要驅動力。 據世界衛生組織稱，包括心血管疾病、癌症、糖尿病和呼吸系統疾病在內的慢性疾病每年導致全球 4,100 萬人死亡。 它影響所有年齡層的人，無論地區或國家。 不健康的飲食、久坐的生活方式、吸菸和酗酒是導致發展中國家和已開發國家慢性病的主要危險因子。 患病率的增加進一步推動了對新藥發現的需求。 為了實現更健康的未來的目標，製藥公司正在加速研發以發現新藥。 新藥的發現涉及治療新的、慢性的和無法治療的疾病的症狀以及解決抗藥性問題。 隨著預期壽命的延長，人們變得更容易感染這些疾病，從而導致全球藥物發現市場不斷增長。

增加藥物發現投資

支持藥品生產，無論是小分子藥物、蛋白質生物製劑、疫苗或體內診斷，都需要大量的公共和私人投資。 這些組織的投資正在為全球藥物發現市場注入活力，幫助實現全球健康目標。 隨著慢性病和新疾病的增加，需要開發和發現新藥物來解決不斷增長的人口的健康問題。 為了滿足這項需求，美國、歐洲和亞太地區的許多生技公司正在大力投資藥物發現。

政府措施

藥物發現是一個耗時且成本高昂的過程，其各個製造步驟都需要政府的資金和支持。 各國政府花費數十億美元用於藥物發現研究和開發。 這筆支出涵蓋各種活動，包括新藥的發現和測試、技術創新的開發以及用於安全監測目的的臨床試驗。 各國政府推出了一系列措施、政策和計劃來支持市場。

生物製品的需求不斷增加

全球藥物發現市場對生物藥物的需求正在快速成長。 生物製品類別正在獲得發展勢頭，因為它具有治療被認為無法治療或難以治療的疾病的巨大潛力。 生物藥物具有治療目標疾病較專一且不易與其他藥物反應的特性。 因此，服用多種藥物的患者的安全性可以得到保證。 這些特性導致對生物製劑的需求迅速增加，包括日本、英國、印度、中國、美國和瑞典在內的許多國家正在開發複雜的生物製劑生產設施，以滿足這種不斷增長的需求。 。

本報告研究和分析了全球藥物發現市場，提供市場規模和預測、市場動態以及主要參與者的現狀和前景。

目錄

第一章研究方法

第 2 章專案範圍與定義

第三章全球藥物發現市場的未來展望

第 4 章執行摘要

第五章全球藥物發現市場展望（2017-2031）

  • 市場規模與預測
    • 金額
    • 數量
  • 依藥物類型
    • 小分子
    • 生物製品
  • 按來源地
    • 自然
    • 合成
  • 按技術
    • 組合化學
    • 高通量篩選
    • 奈米技術
    • 藥物基因組學
    • 其他技術
  • 按最終用戶
    • 製藥公司
    • 合約研究組織
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 市佔率：依公司劃分（2023 年）

第 6 章全球藥物發現市場前景：按地區劃分（2017-2031 年）

  • 北美
    • 市場規模與預測
    • 依藥物類型
    • 按來源地
    • 按技術
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 7 章市場地圖（2023 年）

  • 依藥物類型
  • 按來源地
  • 按技術
  • 按最終用戶
  • 按地區

第八章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制因素）

第 10 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新技術

第十一章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析（2023 年）
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家公司進入市場）
  • 專利分析（如果適用）

第十二章價格分析

第 13 章案例研究

第14章主要公司展望

  • Johnson & Johnson Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • GlaxoSmithKline plc.
  • Bristol Myers Squibb
  • Sanofi Winthrop Industrie
  • AstraZeneca Plc.

第 15 章策略建議

第16章關於我們公司，免責聲明

Product Code: MX10829

Global drug discovery market size was valued at USD 68.24 billion in 2023, which is expected to reach USD 154.12 billion in 2031, with a CAGR of 10.72% for the forecast period between 2024 and 2031F. Growth in global drug discovery market is driven by various factors such as rising prevalence of various chronic diseases, increasing healthcare expenditure, patent expiration of certain popular drugs, adoption of AI solutions, and increasing investments in private and public sector in the biomedical research.

The global drug discovery market is further undergoing robust growth due to an increase in the elderly population. Decrease in fertility rates, increase in life expectancy due to an increase in healthcare facilities, and vast treatment options available worldwide for the elderly population are the factors helping people to live longer. However, it has further accelerated age-related modalities and chronic diseases among the population. To combat these modalities, innovation and research & development in drug discovery are needed. Moreover, each country has its own set of regulations that are responsible to check the safety and efficacy of the approved drug to ensure and maintain the quality and standard of the drug at every step to improve the health of the population.

The COVID-19 pandemic has accelerated the movement of care resulting in increased healthcare expenditure across different countries. The increased healthcare expenditure has surged in global drug discovery market due to increased spending on research, drug development, and manufacturing process. Drug discovery is an expensive, complex, and sensitive process that requires funding from the government and pharmaceutical industry, due to the costs and risks associated with pharmaceutical R&D. Healthcare spending results in better provision of health opportunities that further strengthens the healthcare system of a country and simultaneously leads to the growth of global drug discovery market.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a major driving factor for the global drug discovery market. According to WHO, chronic diseases including cardiovascular diseases, cancer, diabetes, and respiratory illnesses are responsible for 41 million deaths every year at global level. It affects people of all age groups, irrespective of their region and countries. Unhealthy diet, sedentary lifestyle, tobacco use, and alcohol abuse are the leading risk factors for the rising chronic diseases in developing as well as developed countries. The increasing prevalence is further propelling the demand for new drug discoveries. To achieve the goal of a healthier future, pharmaceutical companies are accelerating research and development for discovering new medicines. Drug discoveries are required to treat symptoms of new diseases, chronic diseases, untreatable diseases, and to solve the issue of drug resistance. As life expectancy is increasing, people are more prone to getting exposed to these diseases, resulting in growth of global drug discovery market.

Increased Investments in Drug discovery

Significant public and private investments are needed to support the manufacturing of drugs, whether they are small molecule drugs, protein-based biologic drugs, vaccines, or in vivo diagnostics. These investments by the organizations is thriving the global drug discovery market to meet the global healthcare goals. With increase in chronic diseases and new diseases encounters, the need for developing and discovering new drugs to tackle the health issues of the growing population is the need of the hour. To meet this demand, many biotech companies in USA, Europe, and APAC have raised big investments in drug discoveries.

For instance, in September 2023, Generate Biomedicines raised USD 273 million in a Series C round to advance its generative AI pipeline of preclinical and clinical protein therapeutics. In the same month September 2023, Grit Biotechnology raised USD 60 million in a Series B round. Grit Biotechnology has its specialization in the field of tumor immunotherapy, and this investment will further support its tumor-infiltrating lymphocyte (TIL) pipeline development in the future. Hence, these investments in the drug developing process are expected to accelerate the global drug discovery market.

Government Initiatives

Drug discovery is a time consuming and expensive process and requires funds and support from the government on its various manufacturing steps. The Government has devoted billions for drug discovery R&D. The expenditure has covered a variety of activities such as discovering and testing new drugs, developing innovations, and clinical testing for safety-monitoring purpose. Government has launched many initiatives, policies, and programs to help and support global drug discovery market. For instance, according to an article published by US Government Accountability Office (GAO) on September 2023, The National Institutes of Health (NIH) has identified many viral families that have the potential to cause future pandemics. To combat these viral diseases there is a need to develop antiviral drugs. GAO has identified some technologies like artificial intelligence to speed up antiviral drug development process. In 2022, the White House issued the National Biodefense Strategy and Implementation Plan to support this agenda of antiviral drugs development.

Growing Demand for Biologics

There has been a notable surge in demand for biologics in the global drug discovery market. The category of Biologics is gaining momentum due to its huge potential to treat diseases, which are considered untreatable or difficult to treat. Biologics have attributes that makes them more specific to treat the targeted disease and are less likely to react with other drugs. Hence, they ensure safety of the patients who are taking multiple drugs. These attributes have resulted in an upsurge in demand for biologics and many countries, including Japan, the United Kingdom, India, China, the United States, and Sweden, beginning to develop complex biomanufacturing facilities to meet this rising demand. Major pharmaceutical corporations are entering the biologics space, for instance, in September 2023, Takeda Pharmaceuticals, Inc. got approval from Center for Biologics Evaluation and Research (CBER) for biologics named ADZYNMA, which is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Use of AI in Drug Discovery

Drug development is a long, complex, and uncertain process that takes an average of 10-12 years to develop. The pharmaceutical industry is trying to create a fast and effective solution for drug development, and hence, companies are applying various computational methods to reach that goal. A novel technology called computer-aided drug design, or CADD, is used in the drug discovery process to find and develop a possible lead. Molecular modelling, molecular design, rational drug design and computational chemistry are all part of CADD. The use of AI can simplify and facilitate drug design by filtering datasets available. With the use of healthcare related data available in the records along with latest innovation in AI and Machine learning, it is possible to analyze the data and use it for faster and accurate outcomes. Thus, we can say that use of AI in drug discovery is further accelerating the global drug discovery market.

Many companies are using AI in their drug development process, for instance, on November 21, 2023, Genentech, a member of the Roche Group announced a multi-year strategic research collaboration with NVIDIA to use artificial intelligence (AI) to speed up drug discovery and development. NVIDIA and Genentech collaboration will help Genentech's AI/ML teams, to leverage AI and ML foundational models across numerous research areas including diverse therapeutic modalities as well as will help in gaining new insights, promoting growth in the global drug discovery market.

Future Market Scenario

Global drug discovery market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing global aging population has led to a higher incidence of chronic illnesses such as cardiovascular diseases, cancer, diabetes, respiratory illness, and many more. Additionally, growth in the development of biosimilars and increased use of AI by the drugs manufacturing companies is further propelling the growth in the global drug discovery market. Other important driving factors are governmental support, policies, increase in healthcare expenditure and pharmaceutical regulatory agencies and organizations. The regulatory bodies maintain the safety and efficacy of the newly approved drug by thoroughly examining the drug manufacturing process. Collaborative ventures involving pharmaceutical companies, research institutions, and biotechnology firms have spurred innovation.

Key Players Landscape and Outlook

In the drug discovery market, companies progressively establish strategic partnerships and distribution agreements, which plays a pivotal role in market expansion. These alliances empower firms to harness each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level. These collaborative initiatives promote innovation, expedite product development, and contribute to robust growth in the drug discovery market. In September 2023, Ono Pharmaceutical Co., Ltd., a Japanese firm announced that it has entered into a drug discovery collaboration agreement with Adimab, LLC., which is a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. The collaboration aims to discover and develop innovative antibody drugs in the oncology field.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Future Outlook of Global Drug Discovery Market

4. Executive Summary

5. Global Drug Discovery Market Outlook, 2017-2031F

  • 5.1. Market Size & Forecast
    • 5.1.1. Value
    • 5.1.2. Volume
  • 5.2. By Drug Type
    • 5.2.1. Small Molecules
    • 5.2.2. Biologics
  • 5.3. By Source
    • 5.3.1. Natural
    • 5.3.2. Synthetic
  • 5.4. By Technology
    • 5.4.1. Combinatorial chemistry
    • 5.4.2. High-throughput screening
    • 5.4.3. Nanotechnology
    • 5.4.4. Pharmacogenomics
    • 5.4.5. Other Technologies
  • 5.5. By End-user
    • 5.5.1. Pharmaceutical Companies
    • 5.5.2. Contract Research Organizations
    • 5.5.3. Others
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. South America
    • 5.6.4. Asia-Pacific
    • 5.6.5. Middle East and Africa
  • 5.7. By Company Market Share (%), 2023

6. Global Drug Discovery Market Outlook, By Region, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. Value
      • 6.1.1.2. Volume
    • 6.1.2. By Drug Type
      • 6.1.2.1. Small Molecules
      • 6.1.2.2. Biologics
    • 6.1.3. By Source
      • 6.1.3.1. Natural
      • 6.1.3.2. Synthetic
    • 6.1.4. By Technology
      • 6.1.4.1. Combinatorial chemistry
      • 6.1.4.2. High-throughput screening
      • 6.1.4.3. Nanotechnology
      • 6.1.4.4. Pharmacogenomics
      • 6.1.4.5. Other Technologies
    • 6.1.5. By End-user
      • 6.1.5.1. Pharmaceutical Companies
      • 6.1.5.2. Contract Research Organizations
      • 6.1.5.3. Others
    • 6.1.6. United States*
      • 6.1.6.1. Market Size & Forecast
      • 6.1.6.1.1. Value
      • 6.1.6.1.2. Volume
      • 6.1.6.2. By Drug Type
      • 6.1.6.2.1. Small Molecules
      • 6.1.6.2.2. Biologics
      • 6.1.6.3. By Source
      • 6.1.6.3.1. Natural
      • 6.1.6.3.2. Synthetic
      • 6.1.6.4. By Technology
      • 6.1.6.4.1. Combinatorial chemistry
      • 6.1.6.4.2. High-throughput screening
      • 6.1.6.4.3. Nanotechnology
      • 6.1.6.4.4. Pharmacogenomics
      • 6.1.6.4.5. Other Technologies
      • 6.1.6.5. By End-user
      • 6.1.6.5.1. Pharmaceutical Companies
      • 6.1.6.5.2. Contract Research Organizations
      • 6.1.6.5.3. Others
    • 6.1.7. Canada
    • 6.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Drug Type
  • 7.2. By Source
  • 7.3. By Technology
  • 7.4. By End-user
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Johnson & Johnson Inc.
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Pfizer Inc.
  • 14.4. Novartis AG
  • 14.5. Merck & Co., Inc.
  • 14.6. Amgen, Inc.
  • 14.7. Eli Lilly and Company
  • 14.8. AbbVie Inc.
  • 14.9. GlaxoSmithKline plc.
  • 14.10. Bristol Myers Squibb
  • 14.11. Sanofi Winthrop Industrie
  • 14.12. AstraZeneca Plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 3. Global Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 4. Global Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 5. Global Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 6. Global Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Drug Discovery Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 10. North America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 11. North America Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 12. North America Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 17. United States Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 18. United States Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 19. United States Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 20. United States Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 23. Canada Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 24. Canada Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 25. Canada Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 26. Canada Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 29. Mexico Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 30. Mexico Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 31. Mexico Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 32. Mexico Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 35. Europe Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 36. Europe Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 37. Europe Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 38. Europe Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 42. Germany Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 43. Germany Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 44. Germany Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 45. Germany Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 48. France Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 49. France Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 50. France Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 51. France Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 54. Italy Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 55. Italy Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 56. Italy Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 57. Italy Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 60. United Kingdom Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 61. United Kingdom Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 62. United Kingdom Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 63. United Kingdom Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 66. Russia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 67. Russia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 68. Russia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 69. Russia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 72. Netherlands Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 73. Netherlands Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 74. Netherlands Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 75. Netherlands Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 78. Spain Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 79. Spain Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 80. Spain Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 81. Spain Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 84. Turkey Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Turkey Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 86. Turkey Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 87. Turkey Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 90. Poland Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 91. Poland Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 92. Poland Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 93. Poland Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 96. South America Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 97. South America Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 98. South America Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 99. South America Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 103. Brazil Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 104. Brazil Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 105. Brazil Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 106. Brazil Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 109. Argentina Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 110. Argentina Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 111. Argentina Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 112. Argentina Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 115. Asia-Pacific Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 116. Asia-Pacific Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 117. Asia-Pacific Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 118. Asia-Pacific Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 120. India Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 122. India Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 123. India Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 124. India Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 125. India Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 128. China Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 129. China Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 130. China Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 131. China Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 134. Japan Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Japan Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 136. Japan Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 137. Japan Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 140. Australia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 141. Australia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 142. Australia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 143. Australia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 146. Vietnam Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 147. Vietnam Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 148. Vietnam Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 149. Vietnam Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 152. South Korea Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 153. South Korea Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 154. South Korea Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 155. South Korea Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 158. Indonesia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 159. Indonesia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 160. Indonesia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 161. Indonesia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 164. Philippines Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 165. Philippines Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 166. Philippines Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 167. Philippines Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 170. Middle East & Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Middle East & Africa Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 172. Middle East & Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 173. Middle East & Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Drug Discovery Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 177. Saudi Arabia Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. Saudi Arabia Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 179. Saudi Arabia Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 180. Saudi Arabia Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 183. UAE Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 184. UAE Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 185. UAE Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 186. UAE Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Drug Discovery Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Drug Discovery Market, By Volume, In Million, 2017-2031F
  • Figure 189. South Africa Drug Discovery Market Share (%), By Drug Type, 2017-2031F
  • Figure 190. South Africa Drug Discovery Market Share (%), By Source, 2017-2031F
  • Figure 191. South Africa Drug Discovery Market Share (%), By Technology, 2017-2031F
  • Figure 192. South Africa Drug Discovery Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Source Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023